2025
Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice
Moumneh M, Jamil Y, Nanna M, Damluji A. Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice. Current Treatment Options In Cardiovascular Medicine 2025, 27: 28. DOI: 10.1007/s11936-025-01084-4.Peer-Reviewed Original ResearchDrug-Coated BalloonCoronary artery diseasePercutaneous coronary interventionArtery diseaseIn-stent stenosisAcute coronary syndromeNovel DCBEffective drug deliveryIn-stent restenosisBleeding riskDrug-eluting stentsIncreased bleedingPatient selectionLarge-vessel diseaseStandard treatmentCoronary syndromeClinical indicationsDiabetes mellitusReduce complicationsReviewThe purposeCoronary interventionDe-novo small vessel diseaseClinical casesLesion preparationConsensus groupComparison of Endovascular Interventions for the Treatment of Superficial Femoral Artery Disease: A Network Meta-analysis
Schwartz A, Shah Y, Huang H, Nathan A, Fanaroff A, Giri J, Parikh S, Lansky A, Shah T. Comparison of Endovascular Interventions for the Treatment of Superficial Femoral Artery Disease: A Network Meta-analysis. Journal Of The Society For Cardiovascular Angiography & Interventions 2025, 4: 102432. PMID: 40061407, PMCID: PMC11887560, DOI: 10.1016/j.jscai.2024.102432.Peer-Reviewed Original ResearchPercutaneous transluminal angioplastyCutting Balloon AngioplastyDrug-Coated BalloonBare metal stentsDrug-eluting stentsTreatment of SFA diseaseNetwork Meta-AnalysisSuperficial femoral arteryPrimary patencyTechnical successEndovascular techniquesEndovascular interventionSystematic literature search of PubMedLiterature search of PubMedEndovascular treatment modalitiesMeta-analysisSFA diseaseDe novo lesionsTarget lesion revascularizationSearch of PubMedCritical limb ischemiaSystematic literature searchTreatment modalitiesSuperficial femoral artery diseaseLesion revascularization
2024
Prediction of Health Status in Patients Undergoing Lower Extremity Intervention for Claudication
Peri-Okonny P, Romain G, Callegari S, Cleman J, Vashist A, Smolderen K, Mena-Hurtado C. Prediction of Health Status in Patients Undergoing Lower Extremity Intervention for Claudication. Annals Of Vascular Surgery 2024, 110: 314-322. PMID: 39395588, DOI: 10.1016/j.avsg.2024.08.016.Peer-Reviewed Original ResearchHealth statusPeripheral arterial diseaseEQ-5D VASPeripheral vascular interventionsPredictor of future health statusPredictor of health statusDrug-Coated BalloonLower extremity peripheral arterial diseaseHealth status outcomesFuture health statusEQ-5D-3LHistory of deep venous thrombosisImprove patient outcomesStatus outcomesPrediction of health statusChronic lung diseaseDeep venous thrombosisPlain balloon angioplastyPatient outcomesDisease managementExtremity interventionsApproach to treatmentSD ageVenous thrombosisBaseline characteristics
2023
Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study
Böhme T, Zeller T, Shishehbor M, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh S, Kashyap V, Pietras C, Tirziu D, Beschorner U, Krishnan P, Niazi K, Wali A, Lansky A. Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study. Journal Of Endovascular Therapy 2023, 32: 414-422. PMID: 37314243, DOI: 10.1177/15266028231179589.Peer-Reviewed Original ResearchLutonix drug-coated balloonDrug-coated balloonsPrimary safety endpointDM statusFemoropopliteal diseaseDiabetes mellitusSafety endpointFemoropopliteal lesionsSimilar safetyHigh-risk patient populationFemoropopliteal artery lesionsIschemic rest painNon-DM patientsSymptomatic femoropopliteal lesionsPrimary efficacy endpointMajor adverse eventsTherapy of choiceDrug-Coated BalloonMajor amputationRest painEfficacy endpointPrimary patencyAdverse eventsArtery lesionsDiabetes statusDrug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease
Hanna J, Smolderen K, Castro‐Dominguez Y, Romain G, Lee M, Turner J, Mena‐Hurtado C. Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. Journal Of The American Heart Association 2023, 12: e028622. PMID: 36974774, PMCID: PMC10122876, DOI: 10.1161/jaha.122.028622.Peer-Reviewed Original ResearchConceptsEarly-stage chronic kidney diseaseChronic kidney diseaseBare metal stentsDrug-eluting stentsDrug-coated balloonsMortality riskAmputation riskKidney diseaseSevere chronic kidney diseaseMajor amputation riskPlain balloon angioplastyDrug-Coated BalloonAmputation outcomesCKD statusAmputation rateCause mortalityBackground PatientsAdjusted analysisBalloon angioplastyFemoropopliteal interventionsDES useBMS useRegistry dataDisease trialsPatients
2022
Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study)
Shishehbor MH, Zeller T, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh SA, Kashyap VS, Pietras C, Tirziu D, Ardakani S, Beschorner U, Krishnan P, Niazi KA, Wali AU, Lansky AJ. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation 2022, 145: 1645-1654. PMID: 35377157, DOI: 10.1161/circulationaha.122.059646.Peer-Reviewed Original ResearchConceptsLutonix drug-coated balloonDrug-coated balloonsEnd pointPrimary efficacy end pointPrimary safety end pointIndependent clinical events committeeIschemic rest painPrimary efficacy rateEfficacy end pointPrimary end pointSafety end pointClinical events committeeMajor adverse eventsRate of restenosisDrug-Coated BalloonNoninferiority end pointSafety event rateAverage lesion lengthMajor amputationPopliteal diseaseRest painBailout stentingEfficacy ratePrimary patencyAdverse events
2017
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease
Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, Cardenas J, Werner M, Brodmann M, Mustapha JA, Mena-Hurtado C, Jaff MR, Holden AH, Lyden SP, Mewissen M, Katzen B, Nanjundappa A, Khuddus M, Ricci J, Fry D, Shishehbor M, Bosarge C, Kovach R, Goodwin M, Raja M, Mayeda G, Sandhu J, Rosales O, Crowder W, Paolini D, Henretta J, Desai P, Farhat N, Kang E, Ansel G, Ghani M, Miller W, Pollock C, Korngold E, Angle J, Schultz G, Gensler T, Lopez L, Park J, Al-Khoury G, Joels C, Metzger C. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease. Circulation 2017, 136: 1102-1113. PMID: 28729250, PMCID: PMC5598919, DOI: 10.1161/circulationaha.117.028893.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleFemaleFemoral ArteryHalf-LifeHumansKaplan-Meier EstimateMaleMiddle AgedPaclitaxelPeripheral Arterial DiseaseProspective StudiesSeverity of Illness IndexSingle-Blind MethodTime FactorsTreatment OutcomeVascular PatencyConceptsDrug-coated balloonsPrimary safety end pointSafety end pointTarget lesion revascularizationLesion revascularizationPrimary patencyEnd pointFemoropopliteal diseaseClinical outcomesPivotal studiesDifferent drug-coated balloonsPrimary effectiveness end pointStellarex drug-coated balloonTarget limb major amputationEffectiveness end pointAnkle-brachial indexProcedure-related deathsFemoropopliteal artery diseasePrimary patency rateDrug-Coated BalloonKaplan-Meier estimatesPaclitaxel plasma concentrationsQuality of lifeDCB cohortMajor amputation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply